111 related articles for article (PubMed ID: 25733027)
21. Nonclinical pharmacokinetics and metabolism of EPZ-5676, a novel DOT1L histone methyltransferase inhibitor.
Basavapathruni A; Olhava EJ; Daigle SR; Therkelsen CA; Jin L; Boriack-Sjodin PA; Allain CJ; Klaus CR; Raimondi A; Scott MP; Dovletoglou A; Richon VM; Pollock RM; Copeland RA; Moyer MP; Chesworth R; Pearson PG; Waters NJ
Biopharm Drug Dispos; 2014 May; 35(4):237-52. PubMed ID: 24415392
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics and Disposition of the Thiouracil Derivative PF-06282999, an Orally Bioavailable, Irreversible Inactivator of Myeloperoxidase Enzyme, Across Animals and Humans.
Dong JQ; Varma MV; Wolford A; Ryder T; Di L; Feng B; Terra SG; Sagawa K; Kalgutkar AS
Drug Metab Dispos; 2016 Feb; 44(2):209-19. PubMed ID: 26608081
[TBL] [Abstract][Full Text] [Related]
23. In vitro drug metabolism and pharmacokinetics of a novel thiazolidinedione derivative, a potential anticancer compound.
S S; Vuppu S
J Pharm Biomed Anal; 2020 Feb; 179():113000. PubMed ID: 31787460
[TBL] [Abstract][Full Text] [Related]
24. 3-Methoxylphenylpropyl amides as novel receptor subtype-selective melatoninergic ligands: characterization of physicochemical and pharmacokinetic properties.
Zhu J; Hu Y; Ho MK; Wong YH
Xenobiotica; 2011 Jan; 41(1):35-45. PubMed ID: 21110748
[TBL] [Abstract][Full Text] [Related]
25. Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor.
Lin JH; Chiba M; Balani SK; Chen IW; Kwei GY; Vastag KJ; Nishime JA
Drug Metab Dispos; 1996 Oct; 24(10):1111-20. PubMed ID: 8894513
[TBL] [Abstract][Full Text] [Related]
26. Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches.
Hosea NA; Collard WT; Cole S; Maurer TS; Fang RX; Jones H; Kakar SM; Nakai Y; Smith BJ; Webster R; Beaumont K
J Clin Pharmacol; 2009 May; 49(5):513-33. PubMed ID: 19299532
[TBL] [Abstract][Full Text] [Related]
27. Comparison of pharmacokinetic and metabolic profiling among gossypol, apogossypol and apogossypol hexaacetate.
Jia L; Coward LC; Kerstner-Wood CD; Cork RL; Gorman GS; Noker PE; Kitada S; Pellecchia M; Reed JC
Cancer Chemother Pharmacol; 2008 Jan; 61(1):63-73. PubMed ID: 17356822
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics, oral bioavailability and metabolism of a novel isoquinolinone-based melatonin receptor agonist in rats.
Zhu J; Hu Y; Ho MK; Wong YH
Xenobiotica; 2012 Nov; 42(11):1138-50. PubMed ID: 22642804
[TBL] [Abstract][Full Text] [Related]
29. In Vitro Metabolic Stability and Permeability of Gymnemagenin and Its In Vivo Pharmacokinetic Correlation in Rats - A Pilot Study.
Bera R; Kundu A; Sen T; Adhikari D; Karmakar S
Planta Med; 2016 Apr; 82(6):544-50. PubMed ID: 26916641
[TBL] [Abstract][Full Text] [Related]
30. The Antibiotic Negamycin Crosses the Bacterial Cytoplasmic Membrane by Multiple Routes.
Hörömpöli D; Ciglia C; Glüsenkamp KH; Haustedt LO; Falkenstein-Paul H; Bendas G; Berscheid A; Brötz-Oesterhelt H
Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33468467
[TBL] [Abstract][Full Text] [Related]
31. Preclinical pharmacokinetics and ADME characterization of a novel anticancer chalcone, cardamonin.
Jaiswal S; Shukla M; Sharma A; Rangaraj N; Vaghasiya K; Malik MY; Lal J
Drug Test Anal; 2017 Aug; 9(8):1124-1136. PubMed ID: 27794181
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetic properties of TDP4815 after single intravenous and oral administrations to rat, rabbit, monkey, dog and in vitro drug metabolism.
Chen Y; Cheng D; Tio C; Kagan N; Eisennagel S; Dasgupta M; Tomczuk B; Bone R; Huebert N
Biopharm Drug Dispos; 2008 Apr; 29(3):127-38. PubMed ID: 18186144
[TBL] [Abstract][Full Text] [Related]
33. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: comparative assessement of prediction methods of human clearance.
Ring BJ; Chien JY; Adkison KK; Jones HM; Rowland M; Jones RD; Yates JW; Ku MS; Gibson CR; He H; Vuppugalla R; Marathe P; Fischer V; Dutta S; Sinha VK; Björnsson T; Lavé T; Poulin P
J Pharm Sci; 2011 Oct; 100(10):4090-110. PubMed ID: 21541938
[TBL] [Abstract][Full Text] [Related]
34. Investigation of the rate-determining process in the hepatic elimination of HMG-CoA reductase inhibitors in rats and humans.
Watanabe T; Kusuhara H; Maeda K; Kanamaru H; Saito Y; Hu Z; Sugiyama Y
Drug Metab Dispos; 2010 Feb; 38(2):215-22. PubMed ID: 19875501
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetic characterization of ginsenoside Rh2, an anticancer nutrient from ginseng, in rats and dogs.
Gu Y; Wang GJ; Sun JG; Jia YW; Wang W; Xu MJ; Lv T; Zheng YT; Sai Y
Food Chem Toxicol; 2009 Sep; 47(9):2257-68. PubMed ID: 19524010
[TBL] [Abstract][Full Text] [Related]
36. Development of in vitro pharmacokinetic screens using Caco-2, human hepatocyte, and Caco-2/human hepatocyte hybrid systems for the prediction of oral bioavailability in humans.
Li C; Liu T; Cui X; Uss AS; Cheng KC
J Biomol Screen; 2007 Dec; 12(8):1084-91. PubMed ID: 17989424
[TBL] [Abstract][Full Text] [Related]
37. Preclinical metabolism and pharmacokinetics of SB1317 (TG02), a potent CDK/JAK2/FLT3 inhibitor.
Pasha MK; Jayaraman R; Reddy VP; Yeo P; Goh E; Williams A; Goh KC; Kantharaj E
Drug Metab Lett; 2012 Mar; 6(1):33-42. PubMed ID: 22372550
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics and metabolism of a RAS farnesyl transferase inhibitor in rats and dogs: in vitro-in vivo correlation.
Singh R; Chen IW; Jin L; Silva MV; Arison BH; Lin JH; Wong BK
Drug Metab Dispos; 2001 Dec; 29(12):1578-87. PubMed ID: 11717177
[TBL] [Abstract][Full Text] [Related]
39. Preclinical drug metabolism and pharmacokinetic evaluation of GW844520, a novel anti-malarial mitochondrial electron transport inhibitor.
Xiang H; McSurdy-Freed J; Moorthy GS; Hugger E; Bambal R; Han C; Ferrer S; Gargallo D; Davis CB
J Pharm Sci; 2006 Dec; 95(12):2657-72. PubMed ID: 16892205
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics of (+/-)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate. 3rd communication: plasma concentrations of the unchanged drug and its deethylated metabolite in rats, dogs and monkeys.
Nakamura A; Hirota T; Sugihara K; Morino A
Arzneimittelforschung; 1997 Feb; 47(2):169-74. PubMed ID: 9079236
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
